Eletu Seyi D, Sheppard Carmen L, Thomas Elizabeth, Smith Kenneth, Daniel Priya, Litt David J, Lim Wei Shen, Fry Norman K
Respiratory and Vaccine Preventable Bacteria Reference Unit, National Infection Service, Public Health England, London, United Kingdom.
Respiratory and Vaccine Preventable Bacteria Reference Unit, National Infection Service, Public Health England, London, United Kingdom
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00262-17. Print 2017 Dec.
Current pneumococcal vaccines cover the 10 to 23 most common serotypes of the 92 presently described. However, with the increased usage of pneumococcal-serotype-based vaccines, the risk of serotype replacement and an increase in disease caused by nonvaccine serotypes remains. Serotype surveillance of pneumococcal infections relies heavily on culture techniques, which are known to be insensitive, particularly in cases of noninvasive disease. Pneumococcal-serotype-specific urine assays offer an alternative method of serotyping for both invasive and noninvasive disease. However, the assays described previously cover mainly conjugate vaccine serotypes, give little information about circulating nonvaccine serotypes, and are currently available only in one or two specialist laboratories. Our laboratory has developed a Luminex-based extended-range antigen capture assay to detect pneumococcal-serotype-specific antigens in urine samples. The assay targets 24 distinct serotypes/serogroups plus the cell wall polysaccharide (CWP) and some cross-reactive serotypes. We report that the assay is capable of detecting all the targeted serotypes and the CWP at 0.1 ng/ml, while some serotypes are detected at concentrations as low as 0.3 pg/ml. The analytical serotype specificity was determined to be 98.4% using a panel of polysaccharide-negative urine specimens spiked with nonpneumococcal bacterial antigens. We also report clinical sensitivities of 96.2% and specificities of 89.9% established using a panel of urine specimens from patients diagnosed with community-acquired pneumonia or pneumococcal disease. This assay can be extended for testing other clinical samples and has the potential to greatly improve serotype-specific surveillance in the many cases of pneumococcal disease in which a culture is never obtained.
目前的肺炎球菌疫苗涵盖了目前已描述的92种血清型中10至23种最常见的血清型。然而,随着基于肺炎球菌血清型的疫苗使用增加,血清型替换的风险以及由非疫苗血清型引起的疾病增加的情况仍然存在。肺炎球菌感染的血清型监测严重依赖培养技术,而培养技术已知不够灵敏,尤其是在非侵袭性疾病的情况下。肺炎球菌血清型特异性尿液检测为侵袭性和非侵袭性疾病的血清分型提供了一种替代方法。然而,先前描述的检测主要涵盖结合疫苗血清型,关于循环中的非疫苗血清型的信息很少,并且目前仅在一两个专业实验室可用。我们实验室开发了一种基于Luminex的扩展范围抗原捕获检测方法,用于检测尿液样本中的肺炎球菌血清型特异性抗原。该检测针对24种不同的血清型/血清群以及细胞壁多糖(CWP)和一些交叉反应血清型。我们报告该检测能够在0.1 ng/ml的浓度下检测所有目标血清型和CWP,而一些血清型在低至0.3 pg/ml的浓度下即可检测到。使用一组添加了非肺炎球菌细菌抗原的多糖阴性尿液标本,确定分析血清型特异性为98.4%。我们还报告了使用一组来自诊断为社区获得性肺炎或肺炎球菌疾病患者的尿液标本确定的临床敏感性为96.2%,特异性为89.9%。该检测可扩展用于检测其他临床样本,并且有可能在许多从未进行培养的肺炎球菌疾病病例中大大改善血清型特异性监测。